Panagiotis T Diamantopoulos Maria Michael Olga Benopoulou Efthymia Bazanis George Tzeletas John Meletis George Vayopoulos Nora-Athina Viniou
10.1186/1743-422X-9-1
Virol J
2012 Jan 3;9:1.
CC BY
https://pubmed.ncbi.nlm.nih.gov/22214262/
Anti-Retroviral Agents / administration & dosage Antimetabolites, Antineoplastic / administration & dosage Autoimmune Diseases / drug therapy Azacitidine / administration & dosage HTLV-I Infections / drug therapy Human T-lymphotropic virus 1 / drug effects Myelodysplastic Syndromes / drug therapy
Anti-Retroviral Agents / administration & dosage Antimetabolites, Antineoplastic / administration & dosage Autoimmune Diseases / drug therapy Azacitidine / administration & dosage HTLV-I Infections / drug therapy Human T-lymphotropic virus 1 / drug effects Myelodysplastic Syndromes / drug therapy Case Reports Human T-lymphotropic virus 1 / genetics Human T-lymphotropic virus 1 / isolation & purification Humans Male Middle Aged Polymerase Chain Reaction Treatment Outcome Anti-Retroviral Agents Antimetabolites, Antineoplastic Azacitidine
PMC3305386
22214262
Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations
2012